Executives from Heptares Therapeutics and Oxygen Healthcare (O2h) announced an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.
Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”
Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”
Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h
News May 24, 2010
RELATED ARTICLES
Close to half a million people around the world suffer from a serious hearing impairment. Cochlear implants, whilst useful for some patients, do not help people whose inner ear is damaged or whose auditory nerve does not function properly. Now, researchers have developed a soft variant of an implant that communicates directly with the brainstem.
READ MORE
Machines' ability to learn by processing data gleaned from sensors underlies automated vehicles, medical devices and a host of other emerging technologies. But that learning ability leaves systems vulnerable to hackers in unexpected ways, researchers at Princeton University have found.
Like what you just read? You can find similar content on the communities below.
Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
